Testing two doses of Privigen for children with CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and 17 years old.
- Have confirmed or “possible” CIDP (CIDP symptoms present, as determined by the study team).
- Have CIDP symptoms right now (not absence of symptoms).
- Do NOT have a history (or family history) of inherited nerve disease.
- Do NOT have a past blood clot (thrombotic episode) and do NOT have a severe allergy or reaction risk to Privigen or blood products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
Hear when a new Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.